SENTARA COMMUNITY PLAN
(MEDICAID)

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: **The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request**. All other information may be filled in by office staff; **fax to 1-800-750-9692**. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If the information provided is not complete, correct, or legible, the authorization process can be delayed.**

Drug Requested: Onapgo™ (apomorphine hydrochloride) **subcutaneous continuous infusion**

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____

Member Sentara #: _____ **Date of Birth:** _____

Prescriber Name: _____

Prescriber Signature: _____ **Date:** _____

Office Contact Name: _____

Phone Number: _____ **Fax Number:** _____

NPI #: _____

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Name/Form/Strength: _____

Dosing Schedule: _____ **Length of Therapy**: _____

Diagnosis: _____ **ICD Code, if applicable:** _____

Weight (if applicable): _____ **Date weight obtained:** _____

Recommended Dosage:

- Initial continuous dosage is 1 mg/hr with a maximum of 6 mg/hr for up to 16 hours per day. An extra dose may be titrated in increments of 0.5 mg or 1 mg based on clinical response and tolerability. Subsequent extra doses are between 0.5 mg and 2 mg, with at least 3 hours between extra doses and a maximum of 3 extra doses per day.
- Maximum recommended total daily dosage of Onapgo, including the continuous dosage and any extra dose(s), is 98 mg (1 cartridge per day) generally administered over the waking day (e.g., 16 hours). Quantity Limit: 6 cartons (30 cartridges; 600 mL) per 30 days.

Quantity Limit: 6 cartons (30 cartridges; 600 mL) per 30 days

(Continued on next page)

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

Initial Authorization: 12 months

- ❑ Member must be 18 years of age or older
- ❑ Medication must be prescribed by, or in consultation with a neurologist
- ❑ Member has a diagnosis of Parkinson's disease (PD)
- ❑ Provider has submitted documentation which confirms member's symptoms have **NOT** been adequately controlled with optimal medical therapy using the following agents to treat PD for 28 days or more prior to baseline:
  - ❑ Carbidopa/levodopa (e.g., oral immediate or extended-release levodopa plus a dopa decarboxylase inhibitor)
  - ❑ At least **ONE** other agent used concomitantly from any of the following classes:
    - ❑ Dopamine agonist (e.g., Apokyn® or apomorphine hydrochloride, Neupro®, pramipexole, ropinirole)
    - ❑ Catechol-0-methyl transferase (COMT) inhibitor (e.g., entacapone, Ongentys®, tolcapone)
    - ❑ Monoamine oxidase B (MAO-B) inhibitor (e.g., rasagiline, selegiline, Xadago®)
- ❑ Member is currently experiencing "off" episodes of PD for 2 hours or more a day on average
- ❑ Member is **NOT** currently taking a 5-HT3 antagonist medication such as Zofran® (ondansetron), Kytril® (granisetron), Aloxi® (palonostron), Lotronex® (alosetron), or Anzemet® (dolasetron) which can result in profound hypotension and loss of consciousness **(verified by chart notes and/or pharmacy paid claims)**
- ❑ Medication will **NOT** be used in combination with other apomorphine containing products

Reauthorization: 12 months. Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

- ❑ Member continues to meet all initial criteria
- ❑ Member continues to experience clinical benefit from the requested treatment

Medication being provided by Specialty Pharmacy - PropriumRx

Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.*

Previous therapies will be verified through pharmacy paid claims or submitted chart notes.*

***Approved by Pharmacy and Therapeutics Committee**: ~~11/21/2019; 10/16/2020; 5/22/2025;~~ **11/20/2025**
REVISED/UPDATED/REFORMATTED: ~~2/3/2020; 11/2/2020; 10/11/2021. 6/09/2025, 12/12/2025;~~ **6/29/2026**